After a judge in the U.S. District Court for the District of Delaware ruled as part of the multi-district litigation of patent infringement claims regarding Entresto that the ‘659 patent is invalid, Novartis says it plans to appeal the court ruling on the patent, according to Bloomberg.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVS:
- Bausch + Lomb price target raised to $23 from $19 at BofA
- Bausch + Lomb acquisition of Xiidra a positive, says Barclays
- Novartis says five-year data show Kesimpta suppressed relapse rates
- BLCO Expands Dry Eye Disease Portfolio with Acquisition of Xiidra from Novartis
- Bausch Health’s Bausch + Lomb to acquire Novartis’ XIIDRA